Lucas Kraft
Overview
Explore the profile of Lucas Kraft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ivanochko D, Fabra-Garcia A, Teelen K, van de Vegte-Bolmer M, van Gemert G, Newton J, et al.
Immunity
. 2023 Feb;
56(2):420-432.e7.
PMID: 36792575
Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior understanding of functional epitopes on Pfs230 is based...
2.
Fabra-Garcia A, Hailemariam S, de Jong R, Janssen K, Teelen K, van de Vegte-Bolmer M, et al.
Immunity
. 2023 Feb;
56(2):406-419.e7.
PMID: 36792574
Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that interrupt malaria parasite development in the mosquito, thereby blocking onward transmission, and provide a much-needed tool for malaria control and elimination....
3.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al.
Cell Rep
. 2022 May;
39(7):110812.
PMID: 35568025
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs)...
4.
Cantera J, Cate D, Golden A, Peck R, Lillis L, Domingo G, et al.
ACS Omega
. 2021 Aug;
6(31):20139-20148.
PMID: 34373846
Severe acute respiratory coronavirus-2 (SARS-CoV-2) is a novel viral pathogen and therefore a challenge to accurately diagnose infection. Asymptomatic cases are common and so it is difficult to accurately identify...
5.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al.
bioRxiv
. 2021 May;
PMID: 33972947
In Brief: LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and whose epitope is rarely mutated. Highlights: LY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and known...
6.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
Sci Transl Med
. 2021 Apr;
13(593).
PMID: 33820835
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may...
7.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
bioRxiv
. 2020 Oct;
PMID: 33024963
One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.
8.
Raulin A, Kraft L, Al-Hilaly Y, Xue W, McGeehan J, Atack J, et al.
J Mol Biol
. 2019 May;
431(12):2248-2265.
PMID: 31051176
Apolipoprotein E4 (ApoE4) is one of three (E2, E3 and E4) human isoforms of an α-helical, 299-amino-acid protein. Homozygosity for the ε4 allele is the major genetic risk factor for...
9.
Kraft L, Serpell L, Atack J
Biomolecules
. 2019 Feb;
9(2).
PMID: 30700058
Alzheimer's disease (AD) is the most common type of dementia and, after age, the greatest risk factor for developing AD is the allelic variation of apolipoprotein E (ApoE), with homozygote...
10.
Kraft L, Roe S, Gill R, Atack J
Acta Crystallogr D Struct Biol
. 2018 Oct;
74(Pt 10):973-978.
PMID: 30289407
Lithium, which is still the gold standard in the treatment of bipolar disorder, has been proposed to inhibit inositol monophosphatase (IMPase) and is hypothesized to exert its therapeutic effects by...